Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Vaccine Therapy With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

This study has suspended participant recruitment.
((temporarily not enrolling patients))
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Office of Cancer Complementary and Alternative Medicine
Information provided by (Responsible Party):
University of Washington
ClinicalTrials.gov Identifier:
NCT01922921
First received: August 1, 2013
Last updated: September 6, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)